Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Lillys Zepbound, approved in November 2023 as the Indiana-based drug giants answer to Novo Nordisks Wegovy, showed 21% average weight loss after 72 weeks for its highest dose in its Phase 3 trial, and a mid-stage study of another Lilly experimental medicine, called retatrutide, showed 24% weight loss after just 48 weeks
cnidos December 14, 2023, 3:13pm 49 Thats actually an interesting anecdote
Wildly different doses
It comes in two forms: Subcutaneous injections Oral tablet Novo Nordisk originally developed semaglutide drugs to manage diabetes and obesity
Hebah Almahariq: contributed to design, interpretation, drafted and critically revised the manuscript and gave final approval
US$ 27.58
US$ 25.50
US$ 24.64
US$ 24.24
US$ 21.12
